Regencell Bioscience (NASDAQ:RGC) Trading Down 4.6% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares fell 4.6% during mid-day trading on Thursday . The company traded as low as $6.03 and last traded at $6.02. Approximately 145,481 shares were traded during mid-day trading, a decline of 51% from the average session volume of 297,599 shares. The stock had previously closed at $6.31.

Analysts Set New Price Targets

Several brokerages have issued reports on RGC. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. Wall Street Zen lowered shares of Regencell Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Regencell Bioscience presently has a consensus rating of “Sell”.

Regencell Bioscience Trading Down 0.2%

The stock has a fifty day moving average price of $5.75 and a two-hundred day moving average price of $18.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RGC. Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience during the second quarter worth approximately $1,701,000. BNP Paribas Financial Markets bought a new stake in shares of Regencell Bioscience in the second quarter valued at approximately $768,000. XTX Topco Ltd bought a new stake in shares of Regencell Bioscience in the third quarter valued at approximately $598,000. Vident Advisory LLC grew its position in Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after buying an additional 11,866 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after acquiring an additional 17,143 shares in the last quarter. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.